Retatrutide is the most talked about next generation option, targeting three hormone pathways instead of one or two
Primary Claim: 46% More Weight Loss According to publicly available disclosures on the company's website, Ivm Health states that "Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks." The company explicitly states this was "not a head-to-head study," meaning Ivm patients were not directly randomized against a control group in the same trial
Their results were consistent with findings in mice showing that the use of an immunotherapy drug to boost the immune response can increase the risk or severity of tuberculosis, Dr
Most healthcare providers advise against using spironolactone while breastfeeding or suggest choosing an alternative feeding method if the medication is essential
The therapy is not dangerous
Weight Fluctuations: Some individuals have reported unintended weight gain or loss, though evidence on this is limited
